Last reviewed · How we verify
MK-8237 tablets
MK-8237 is an oral immunotherapeutic agent designed to modulate immune responses, likely through toll-like receptor (TLR) signaling or related innate immune pathways.
MK-8237 is an oral immunotherapeutic agent designed to modulate immune responses, likely through toll-like receptor (TLR) signaling or related innate immune pathways. Used for Allergic rhinitis and related allergic conditions (Phase 3).
At a glance
| Generic name | MK-8237 tablets |
|---|---|
| Also known as | SCH 900237 |
| Sponsor | ALK-Abelló A/S |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
MK-8237 appears to function as an immune modulator that enhances or redirects immune responses against disease targets. The exact molecular mechanism remains proprietary, but the compound is being developed for conditions where immune system activation or rebalancing is therapeutically beneficial.
Approved indications
- Allergic rhinitis and related allergic conditions (Phase 3)
Common side effects
Key clinical trials
- MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009) (PHASE1)
- A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627) (PHASE2)
- Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607) (PHASE3)
- Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK-8237 tablets CI brief — competitive landscape report
- MK-8237 tablets updates RSS · CI watch RSS
- ALK-Abelló A/S portfolio CI